Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination with Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumours.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Bortezomib (Primary) ; Doxorubicin; Gemcitabine
- Indications Urogenital cancer
- Focus Adverse reactions
- 24 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 22 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.
- 22 Mar 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016, as reported by ClinicalTrials.gov.